9 completed, 3 active not recruiting, 3 recruiting, 2 unknown. 18 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 9, Active not recruiting 3, Recruiting 3, Unknown 2, Terminated 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Peritoneal Cancer: new trials by email Literature Review of Peritoneal Cancer trials Research Report on Peritoneal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 646 | 2026-10-07 | 2026-10-30 |
| A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) R-DXd, Bevacizumab - Ovarian Cancer, Ovarian Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 802 | 2026-09-18 | 2026-10-29 |
| Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab - Ovarian Cancer, Peritoneal Cancer | Phase 3 | Active not recruiting | AbbVie | 520 | 2023-03-15 | 2026-06-02 |
| Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer Carboplatin, Paclitaxel, Bevacizumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | AGO Study Group | 970 | 2022-09-13 | 2025-09-10 |
| A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer Mirvetuximab Soravtansine - Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 3 | Unknown | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 35 | 2022-08-18 | 2022-11-21 |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib Rucaparib - Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer | Phase 3 | Completed | pharmaand GmbH | 34 | 2021-03-22 | 2024-05-07 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Oregovomab, Paclitaxel, Carboplatin - Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 3 | Active not recruiting | CanariaBio Inc. | 615 | 2020-08-25 | 2026-04-01 |
| A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Mirvetuximab Soravtansine - Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 3 | Completed | ImmunoGen, Inc. | 106 | 2020-07-23 | 2024-08-07 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRĪ±) Expression Mirvetuximab Soravtansine, Paclitaxel, Topotecan - Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 3 | Completed | AbbVie | 453 | 2019-12-31 | 2025-08-27 |
| Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer Two cycles of neoadjuvant chemotherapy - Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV | Phase 3 | Unknown | Seoul National University Hospital | 298 | 2018-12-19 | 2019-12-10 |
| Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway Local Anesthetic Solution, Bupivacaine HCl, Liposomal Bupivacaine - Peritoneal Cancer | Phase 3 | Completed | M.D. Anderson Cancer Center | 75 | 2017-11-27 | 2022-02-18 |
| Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases Perioperative systemic therapy, Perioperative CAPOX-bevacizumab, Perioperative FOLFOX-bevacizumab - Colorectal Neoplasm, Colorectal Cancer | Phase 2 / Phase 3 | Active not recruiting | Koen Rovers | 358 | 2017-06-01 | 2026-03-24 |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Chemotherapy, Rucaparib - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 3 | Completed | pharmaand GmbH | 349 | 2017-03-01 | 2023-06-09 |
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) Rucaparib, Placebo - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | pharmaand GmbH | 564 | 2014-04-07 | 2023-06-09 |
| Accelerating Gastrointestinal Recovery Alvimopan, Placebo - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | Jamie N. Bakkum-Gamez | 146 | 2013-01-01 | 2016-10-24 |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer AMG 386, Paclitaxel, AMG 386 Placebo - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Terminated | Amgen | 1015 | 2012-01-01 | 2017-02-23 |
| Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Early post-operative enteral feeding - Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 3 | Completed | Queensland Centre for Gynaecological Cancer | 109 | 2009-01-01 | 2014-06-12 |
| Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane Tamoxifen, Chemotherapy - Ovarian Cancer, Peritoneal Cancer | Phase 3 | Completed | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 241 | 2002-03-01 | 2016-04-05 |
Fallopian Tube Neoplasms (16) · Ovarian Neoplasms (13) · Carcinoma, Ovarian Epithelial (7) · Neoplasms (2) · Peritoneal Neoplasms (2) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Genital Neoplasms, Male (1) · Hyperthermia (1) · Malnutrition (1) · Prostatic Neoplasms (1) · Recurrence (1)
Neoplasms by Site (17) · Adnexal Diseases (16) · Endocrine Gland Neoplasms (16) · Endocrine System Diseases (16) · Fallopian Tube Diseases (16) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Genital Diseases (16) · Genital Diseases, Female (16) · Genital Neoplasms, Female (16) · Gonadal Disorders (16) · Ovarian Diseases (16) · Urogenital Diseases (16) · Urogenital Neoplasms (16) · Neoplasms (15)
Paclitaxel (8) · Carboplatin (6) · Bevacizumab (4) · mirvetuximab soravtansine (4) · liposomal doxorubicin (3) · rucaparib (3) · Drug Therapy (2) · Gemcitabine (2) · Bupivacaine (1) · CP protocol (1) · Cisplatin (1) · Tamoxifen (1) · Topotecan (1) · alvimopan (1) · niraparib (1)
pharmaand GmbH (3) · AbbVie (2) · Merck Sharp & Dohme LLC (2) · AGO Study Group (1) · Amgen (1) · CanariaBio Inc. (1) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (1) · ImmunoGen, Inc. (1) · Jamie N. Bakkum-Gamez (1) · Koen Rovers (1) · M.D. Anderson Cancer Center (1) · Nordic Society of Gynaecological Oncology - Clinical Trials Unit (1) · Queensland Centre for Gynaecological Cancer (1) · Seoul National University Hospital (1)
United States (11) · Israel (8) · Italy (8) · Belgium (7) · Canada (7) · Spain (7) · Germany (6) · South Korea (6) · Australia (5) · Czechia (5) · Poland (5) · United Kingdom (5) · Russia (4) · Taiwan (4) · Brazil (3)
Alexandra R Brandt-Kerkhof, MD (1) · Andreas Obermair, MD FRANZCOG CGO (1) · Arend G Aalbers, MD (1) · Cornelis J Punt, MD, PhD (1) · Eino B van Duyn, MD, PhD (1) · Gunnar B Kristensen, Prof (1) · Hee Seung Kim, MD/PhD (1) · Heidi Giordano (1) · Ignace H de Hingh, MD, PhD (1) · Jamie Bakkum-Gamez, MD (1) · Juan P. Cata, MD (1) · Jurriaan B Tuynman, MD, PhD (1) · Marinus J Wiezer, MD, PhD (1)
PMID 37185961, PMID 25827292, PMID 28916367, PMID 31023318, PMID 31076365, PMID 32359490, PMID 32375688, PMID 32861537, PMID 33528867, PMID 34009291, PMID 35170751, PMID 35298906, PMID 35397664, PMID 36716407, PMID 37212825, PMID 37262961, PMID 37935524, PMID 38055253, PMID 38858103, PMID 39082675, PMID 39914419, PMID 40179908, PMID 42372745
2016 (2), 2025 (2), 2019 (1)